Affordable Access

Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.

Authors
Type
Published Article
Journal
Oncotarget
1949-2553
Publisher
"Impact Journals, LLC "
Publication Date
Volume
4
Issue
8
Pages
1253–1265
Identifiers
PMID: 23896512
Source
Medline

Abstract

Statistics

Seen <100 times